{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:50:33Z","timestamp":1785801033202,"version":"3.56.0"},"reference-count":22,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Education, Culture, Sports, Science and Technology, Japan","award":["JP24K09547"],"award-info":[{"award-number":["JP24K09547"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Background: Episodic ataxia type 2 (EA2) is a rare disorder characterized by paroxysmal gait instability, dysarthria, and dizziness. It is caused by CACNA1A mutations. Spinocerebellar ataxia type 6 (SCA6) rarely causes episodic ataxia-like symptoms. Acetazolamide has limited effectiveness for treating episodic ataxia. Methods: We investigated the effect of drug therapy in two patients with EA2 and one patient with SCA6 who presented with episodic ataxia. All three cases were CACNA1A-associated diseases. Results: In these three cases, acetazolamide administration was partially and transiently effective for episodic ataxia attacks. After levetiracetam addition, the number of ataxic attacks was significantly reduced, although the durations of attacks were not changed. The effect of levetiracetam was stable and continued for seven years. Levetiracetam and acetazolamide reduced chronic cerebellar ataxia in an SCA6 patient. Conclusions: In this small number of cases, levetiracetam was considered effective in two patients with EA2 and mildly effective in one patient with SCA6.<\/jats:p>","DOI":"10.3390\/genes16030335","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T06:53:00Z","timestamp":1741848780000},"page":"335","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effects of Levetiracetam on Episodic Ataxia Type 2 and Spinocerebellar Ataxia Type 6 with Episodic Ataxic Symptoms: A Case Series"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0628-7164","authenticated-orcid":false,"given":"Haruo","family":"Shimazaki","sequence":"first","affiliation":[{"name":"Department of Common Education, Faculty of Health and Medical Care, Saitama Medical University, Saitama 350-1241, Japan"},{"name":"Department of Neurology, Jichi Medical University, Tochigi 329-0498, Japan"},{"name":"Department of Neurology, Saitama Medical University, Saitama 350-0495, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1111\/ene.15969","article-title":"Genotype-phenotype relations for episodic ataxia genes: MDSGene systematic review","volume":"30","author":"Olszewska","year":"2023","journal-title":"Eur. J. Neurol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0092-8674(00)81373-2","article-title":"Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4","volume":"87","author":"Ophoff","year":"1996","journal-title":"Cell"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/ng0197-62","article-title":"Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel","volume":"15","author":"Zhuchenko","year":"1997","journal-title":"Nat. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1093\/hmg\/6.11.1973","article-title":"Episodic ataxia type 2 (EA2) and spinocerebellar ataxia type 6 (SCA6) due to CAG repeat expansion in the CACNA1A gene on chromosome 19p","volume":"6","author":"Jodice","year":"1997","journal-title":"Hum. Mol. Genet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1212\/WNL.28.12.1259","article-title":"Hereditary paroxysmal ataxia: Response to acetazolamide","volume":"28","author":"Griggs","year":"1978","journal-title":"Neurology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1212\/01.WNL.0000125691.74109.53","article-title":"Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine","volume":"62","author":"Strupp","year":"2004","journal-title":"Neurology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.1212\/CPJ.0000000000001017","article-title":"Fampridine and Acetazolamide in EA2 and Related Familial EA: A Prospective Randomized Placebo-Controlled Trial","volume":"11","author":"Muth","year":"2021","journal-title":"Neurol. Clin. Pract."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1111\/ene.13327","article-title":"Effectiveness of levetiracetam in an acetazolamide-unresponsive patient with episodic ataxia type 2 by a novel CACNA1A nonsense mutation","volume":"24","author":"Lee","year":"2017","journal-title":"Eur. J. Neurol."},{"key":"ref_9","first-page":"446","article-title":"A sporadic case of episodic ataxia with nystagmus (EA-2)","volume":"38","author":"Namekawa","year":"1998","journal-title":"Rinsho Shinkeigaku"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1212\/WNL.52.9.1816","article-title":"High prevalence of CACNA1A truncations and broader clinical spectrum in episodic ataxia type 2","volume":"52","author":"Denier","year":"1999","journal-title":"Neurology"},{"key":"ref_11","first-page":"63","article-title":"A case of spinocerebellar ataxia type 6 with its initial symptom of episodic ataxia-like phenotype","volume":"58","author":"Shimazaki","year":"2006","journal-title":"No To Shinkei"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1007\/s10072-021-05368-y","article-title":"Efficacy of levetiracetam in patients with episodic ataxia type 2 caused by CACNA1A mutation: Three case reports","volume":"42","author":"Na","year":"2021","journal-title":"Neurol. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1212\/WNL.0b013e318225ab07","article-title":"A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias","volume":"77","author":"Strupp","year":"2011","journal-title":"Neurology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1086\/318804","article-title":"Complete loss of P\/Q calcium channel activity caused by a CACNA1A missense mutation carried by patients with episodic ataxia type 2","volume":"68","author":"Guida","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.nbd.2017.07.004","article-title":"Characterization of the dominant inheritance mechanism of Episodic Ataxia type 2","volume":"106","author":"Dorgans","year":"2017","journal-title":"Neurobiol. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1093\/hmg\/ddl080","article-title":"C-termini of P\/Q-type Ca2+ channel alpha1A subunits translocate to nuclei and promote polyglutamine-mediated toxicity","volume":"15","author":"Kordasiewicz","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Contreras-Garcia, I.J., Cardenas-Rodriguez, N., Romo-Mancillas, A., Bandala, C., Zamudio, S.R., Gomez-Manzo, S., Hernandez-Ochoa, B., Mendoza-Torreblanca, J.G., and Pichardo-Macias, L.A. (2022). Levetiracetam Mechanisms of Action: From Molecules to Systems. Pharmaceuticals, 15.","DOI":"10.3390\/ph15040475"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.bbrc.2016.07.020","article-title":"Keeping Our Calcium in Balance to Maintain Our Balance","volume":"483","author":"Mark","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ishikawa, T., Tomatsu, S., Tsunoda, Y., Lee, J., Hoffman, D.S., and Kakei, S. (2014). Releasing dentate nucleus cells from Purkinje cell inhibition generates output from the cerebrocerebellum. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0108774"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/00001756-200303030-00035","article-title":"Levetiracetam reduces caffeine-induced Ca2+ transients and epileptiform potentials in hippocampal neurons","volume":"14","author":"Angehagen","year":"2003","journal-title":"Neuroreport"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Nardello, R., Plicato, G., Mangano, G.D., Gennaro, E., Mangano, S., Brighina, F., Raieli, V., and Fontana, A. (2020). Two distinct phenotypes, hemiplegic migraine and episodic Ataxia type 2, caused by a novel common CACNA1A variant. BMC Neurol., 20.","DOI":"10.1186\/s12883-020-01704-5"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4296","DOI":"10.1007\/s00415-021-10555-0","article-title":"Epilepsy and episodic ataxia type 2: Family study and review of the literature","volume":"268","author":"Verriello","year":"2021","journal-title":"J. Neurol."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/16\/3\/335\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:52:55Z","timestamp":1760028775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/16\/3\/335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["genes16030335"],"URL":"https:\/\/doi.org\/10.3390\/genes16030335","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,13]]}}}